Alka Rebentish, MD
Infectious Disease · Las Vegas, NVNPI 1427012806
Payments from drug & device makers
Across 834 payments — averaging $27.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$7K
- Viiv Healthcare Company$4K
- AbbVie$3K
- Merck$1K
- Astellas Pharma US Inc$1K
- Melinta Therapeutics, LLC$925
- plus $6K from 27 others
What the payments were for
- Consulting fees$3,14014%
- Speaking & faculty fees$240%
- Travel & lodging$1,2455%
- Food & beverage$17,20576%
- Education$1,0655%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 137 | $6,736 |
| Viiv Healthcare Company | 198 | $3,772 |
| AbbVie(2 entities) | 123 | $2,506 |
| Merck | 78 | $1,481 |
| Astellas Pharma US Inc | 38 | $1,190 |
| Melinta Therapeutics, LLC | 30 | $925 |
| Cipla USA Inc. | 5 | $899 |
| Shionogi Inc | 35 | $693 |
| Johnson & Johnson | 39 | $639 |
| Paratek Pharmaceuticals, Inc. | 42 | $605 |
| Insmed, Inc. | 18 | $480 |
| Ferring Pharmaceuticals Inc. | 13 | $297 |
| Theratechnologies Inc. | 12 | $282 |
| Philips North America LLC | 15 | $244 |
| Napo Pharmaceuticals Inc | 16 | $240 |
| AstraZeneca(2 entities) | 2 | $224 |
| Janssen Products, LP | 2 | $200 |
| Pfizer | 6 | $198 |
| Amgen | 2 | $152 |
| UCB, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $120 |
| Novo Nordisk | 1 | $111 |
| Bristol Myers Squibb | 1 | $110 |
| Aimmune Therapeutics, Inc. | 4 | $98 |
| Lilly USA, LLC | 1 | $73 |
| La Jolla Pharmaceutical Company | 2 | $62 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $60 |
| Janssen Scientific Affairs, LLC | 2 | $43 |
| Dynavax Technologies Corporation | 3 | $39 |
| T2 Biosystems, Inc. | 1 | $21 |
| Vyera Pharmaceuticals, LLC | 1 | $21 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Leadiant Biosciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,678 in reported general payments places this provider in the 85th percentile of 65 infectious disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 219 | $859,119 |
| DovatoDolutegravir Sodium/Lamivudine | 48 | $145,154 |
| CabenuvaCabotegravir/Rilpivirine | 20 | $132,085 |
| Daptomycin | 54 | $57,278 |
| TivicayDolutegravir Sodium | 19 | $44,825 |
| DescovyEmtricitabine/Tenofov Alafenam | 15 | $34,102 |
| ErtapenemErtapenem Sodium | 44 | $26,511 |
| VemlidyTenofovir Alafenamide | 18 | $25,603 |
| Cefepime Hcl | 22 | $5,264 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 28 | $3,051 |
| Rifampin | 45 | $2,955 |
| CeftriaxoneCeftriaxone Sodium | 48 | $2,408 |
| Meropenem | 13 | $2,157 |
| Vancomycin Hcl | 20 | $1,874 |
| Azithromycin | 34 | $1,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Vemlidy | $6,736 | $918,823252 claims |
| Viiv Healthcare CompanyDovato, Cabenuva, Tivicay | $3,772 | $322,06487 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 65 infectious disease providers in Nevada.
Other infectious disease in Las Vegas
- Alireza FarabiLas Vegas$2M
- Dhiresh JoshiLas Vegas$216K
- Shadaba AsadLas Vegas$107K
- Shaker ItaniLas Vegas$52K
- Dhaval ShahLas Vegas$27K
- Ronald ShockleyLas Vegas$13K
- Chukwudum UcheLas Vegas$13K
- John OreillyLas Vegas$8K
- Li-Chien ChenLas Vegas$8K
- Naima ZaheerLas Vegas$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.